Lifestyle program participation: Member is using Wegovy in combination with a lifestyle modification program that encourages reduced calorie diet and increased physical activity; provider must specify duration (months) of active participation and attach supporting documentation (examples: provider chart notes, recurring program receipts, dietary logs, recurring nutrition counseling appointments).
Attach one form of documentation for diet and one for physical activity as listed on the form.
Prior weight-loss therapies: Provide prior weight-loss medications tried and failed with dates (examples: Contrave, Saxenda, Qsymia, Xenical, Zepbound, prior Wegovy) and attach documentation.
List dates of therapy for each prior medication trial.
Baseline measures: Provide baseline (prior to any weight-loss medication) height, weight, and BMI with supporting documentation (for example, chart notes).
Concurrent GLP-1 use: Document whether Wegovy is being used with another GLP-1 receptor agonist or GLP-1 combinations (for example, with insulin); indicate current use on the form.
Zepbound intolerance: If asserted, document therapeutic intolerance or contraindication to Zepbound (severe side effects not resolved by diet modification or dose de‑escalation, or documented allergic reaction/hypersensitivity) with supporting documentation.
Cardiovascular use and comorbidity: Document whether Wegovy is being used for major adverse cardiovascular event risk reduction, presence of pre-existing cardiovascular disease (prior stroke or myocardial infarction), peripheral arterial disease (and supporting ABI, revascularization, or amputation documentation), diabetes or prediabetes status, and current standard pharmacologic therapy for comorbid conditions.
Attach chart notes when applicable.
MASH/NASH-specific requirements: If Wegovy is used for Metabolic‑Dysfunction Associated Steatohepatitis (MASH/NASH): indicate prescribing specialty (gastroenterologist/hepatologist), provide confirmatory testing (biopsy, NITs, ELF) with dates, provide fibrosis staging (F0–F4), document risk factors (BMI, waist circumference, fasting glucose, 2‑hour glucose, HbA1c, triglycerides, HDL, blood pressure), confirm absence of cirrhosis/hepatic decompensation/HCC, document alcohol intake within limits, and provide evidence of continued use of standard‑of‑care pharmacologic treatments for comorbid diseases.
If MASH/NASH is selected, complete and attach documentation for questions 22–31 on the form.
Statin intolerance assessment: If statin intolerance is reported, document specific severe events (for example, hospitalization for rhabdomyolysis, CK/LFT elevations) and trials of at least two different statins that resolved on discontinuation.
Select hospitalization or other severe event as applicable and attach supporting documentation.